News and Events

Press Releases

2011

Jun 05 2011	Versartis Long-Term Preclinical Safety Data for VRS-317 Presented at ENDO 2011
Mar 28 2011	Versartis Initiates Phase 1 Clinical Trial of VRS-317 Monthly Human Growth Hormone Therapy
Feb 16 2011	Versartis Completes $21 Million Series B Financing

Oct 04 2010	Versartis CEO Presents Positive Preclinical Data on Long-Acting Growth Hormone at International Congress of the GRS and IGF Society
Sep 21 2010	Versartis Presents Data at EASD for New Diabetes Drug VRS-859 (exenatide-XTEN)
Jun 26 2010	Versartis Data for Type 2 Diabetes Drug VRS-859 (exenatide-XTEN) Featured at American Diabetes Association Annual Scientific Meeting
Jun 22 2010	Versartis Initiates First Clinical Trial for New Diabetes Drug VRS-859 (exenatide-XTEN)
Jun 20 2010	Versartis Presents Results of Three Studies at ENDO 2010
Apr 21 2010	Versartis CEO Jeffrey Cleland Featured at Advancing Protein Therapeutics Conference
Apr 14 2010	Paul Westberg Joins Versartis as Senior Vice President, Business Development
Mar 26 2010	Versartis to Present New Data at International Congress on Endocrinology
Jan 11 2010	Versartis to Present at Biotech Showcase in San Francisco
Nov 15 2009	XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics
Sep 23 2009	Versartis Presents Preclinical Data for Novel Type 2 Diabetes Drug
Sep 14 2009	Versartis to Provide Update on Product Pipeline at Two Technology Conferences
Aug 17 2009	SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
Jun 10 2009	Versartis Presents Positive Preclinical Data on Two Product Candidates at ENDO 09
Jun 05 2009	Versartis Publishes Preclinical Abstracts for Two Product Candidates at 2009 American Diabetes Association Scientific Sessions
Jun 02 2009	Versartis, Inc. Completes Series A Funding of $11 Million [€7.9 M] in a Joint Venture between Index Ventures and Amunix, Inc.